Support Line: 0300 373 8500
Some people with non-Hodgkin Lymphoma have a protein called CD20 on their B-cells. This study is focussed on a type of treatment that targets this protein, giving researchers insight into what the right dosage is, and looking at different ways of giving the drug.
This study closed on 21st August 2025.
• Confirmed WM diagnosis; and are documented as having the CD20 protein
• Previously been treated with a minimum of two lines of systemic therapy, including at least one line of anti-CD-20 treatment
• No further standard options remaining